AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
P/E ratio for AbCellera Biologics Inc. (ABCL)
P/E ratio as of 2023: -11.28
According to AbCellera Biologics Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -11.28. At the end of 2022 the company had a P/E ratio of 18.22.
P/E ratio history for AbCellera Biologics Inc. from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -11.28 |
| 2022 | 18.22 |
| 2021 | 25.70 |
| 2020 | 91.19 |
| 2019 | -3750.57 |
| 2018 | 45313.64 |
| 2001 | 0.00 |